effect of melatonin on prevention of delirium in admitted patients

A study of the effect of melatonin on prevention of delirium in Intensive Care Unite (ICU) inpatients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017061234482N1

Enrollment

Registered

2017-09-01

Start date

2017-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium, not induced by alcohol and other psychoactive substances

Interventions

Placebo

Intervention group: 3 mg melatonin at 9 p.m for a week or till discharge from ICU

control group: Placebo tab at 9 p.m for a week or till discharge from ICU

Intervention 1: Intervention group: 3 mg melatonin at 9 p.m for a week or till discharge from ICU. Intervention 2: control group: Placebo tab at 9 p.m for a week or till discharge from ICU.

Prevention

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Ag 18 or above; admitted in ICU; Consciousness Exclusion criteria: Dementia; Critically ill patients; having contraindication of melatonin use; being a current user of melatonin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Delirium incidence. Timepoint: Daily. Method of measurement: CAM-ICU.	—

Secondary

Measure	Time frame
Number of admition days. Timepoint: after discharge from hospital. Method of measurement: patient records.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Shirzadi

Kermanshah University Of Medical Science

m_shirzadi@kums.ac.ir+98 83 3427 6310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026